Baidu
map

J Allergy Clin Immunol:靶向Bet v 1的新抗体鸡尾酒能迅速而持续地治疗白桦树过敏症状

2021-07-06 AlexYang MedSci原创

在欧洲和美国,临床上对白桦树花粉的过敏影响了大约20%-30%的过敏人群。

在欧洲和美国,临床上对白桦树花粉的过敏影响了大约20%-30%的过敏人群。

白桦树花粉在树木花粉季节盛行,根据地理位置的不同,盛行时间在冬末至夏初的4至8周内。白桦树花粉含有混合的致敏和非致敏蛋白,其中Bet v 1是免疫优势和最丰富的致敏蛋白。据报道,白桦树过敏者对Bet v 1的过敏率高达95%以上。

过敏原特异性IgG混合治疗猫过敏的疗效表明,过敏原特异性IgG可能是由过敏原免疫疗法引起的一种主要保护机制。为了扩展这些发现,近期,有研究人员在白桦树过敏的受试者中测试了Bet v 1特异性抗体鸡尾酒疗法

研究是一期、随机、双盲的研究。A部分,在32名健康受试者中使用递增剂量的Bet v 1-特异性抗体鸡尾酒 "REGN5713/14/15" (150-900 mg);B部分,在64名桦树过敏受试者中使用单次皮下900 mg剂量或安慰剂。在筛查和第8、29、57和113天(仅SPT)评估鼻部症状总分(TNSS)对滴定白桦树提取物鼻腔过敏原挑战(NAC)和白桦树和赤杨树过敏原皮刺试验(SPT)的反应;还进行了嗜碱细胞活化试验(n=26)。

相对于基线,单剂量REGN5713/14/15显著降低了桦木NAC后的TNSS。与安慰剂相比,TNSS的AUC(0-1小时)差异(第8天:-1.17,P=0.001;第29天:-1.18,P=.001;第57天:-0.85,P=0.024)和滴定白桦树SPT的AUC差异(所有P<0.001)持续了≥2个月;在赤杨树SPT观察到了类似结果。另外,REGN5713/14/15耐受性良好。更多的是,REGN5713/14/15治疗的受试者与安慰剂相比,在第8天、第57天和第113天,嗜碱细胞对白桦树相关过敏原的反应性明显下降(所有P<0.01)。

单剂量REGN5713/14/15 900mg SC治疗效果

综上所述,单剂量REGN5713/14/15的耐受性良好,并能快速(1周)和持久(2个月)地减少桦树过敏原NAC后的过敏症状,为治疗白桦树过敏症状提供了一个新的范例

原始出处:

Philippe Gevaert , Jarno De Craemer , Natalie De Ruyck et al. Novel antibody cocktail targeting Bet v 1 rapidly and sustainably treats birch allergy symptoms in a Phase 1 study. J Allergy Clin Immunol. Jun 2021

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1761631, encodeId=e1e31e6163159, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Mar 21 23:09:27 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037495, encodeId=f51e203e4955a, content=<a href='/topic/show?id=d4189406ec0' target=_blank style='color:#2F92EE;'>#过敏症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94067, encryptionId=d4189406ec0, topicName=过敏症状)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Feb 17 13:09:27 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329524, encodeId=c8d713295244a, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Jul 08 10:09:27 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516462, encodeId=90a51516462f0, content=<a href='/topic/show?id=0c06940668a' target=_blank style='color:#2F92EE;'>#过敏症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94066, encryptionId=0c06940668a, topicName=过敏症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=def310968681, createdName=ms1948154235210413, createdTime=Thu Jul 08 10:09:27 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574835, encodeId=bcec15e48355e, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Thu Jul 08 10:09:27 CST 2021, time=2021-07-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1761631, encodeId=e1e31e6163159, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Mar 21 23:09:27 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037495, encodeId=f51e203e4955a, content=<a href='/topic/show?id=d4189406ec0' target=_blank style='color:#2F92EE;'>#过敏症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94067, encryptionId=d4189406ec0, topicName=过敏症状)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Feb 17 13:09:27 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329524, encodeId=c8d713295244a, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Jul 08 10:09:27 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516462, encodeId=90a51516462f0, content=<a href='/topic/show?id=0c06940668a' target=_blank style='color:#2F92EE;'>#过敏症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94066, encryptionId=0c06940668a, topicName=过敏症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=def310968681, createdName=ms1948154235210413, createdTime=Thu Jul 08 10:09:27 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574835, encodeId=bcec15e48355e, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Thu Jul 08 10:09:27 CST 2021, time=2021-07-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1761631, encodeId=e1e31e6163159, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Mar 21 23:09:27 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037495, encodeId=f51e203e4955a, content=<a href='/topic/show?id=d4189406ec0' target=_blank style='color:#2F92EE;'>#过敏症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94067, encryptionId=d4189406ec0, topicName=过敏症状)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Feb 17 13:09:27 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329524, encodeId=c8d713295244a, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Jul 08 10:09:27 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516462, encodeId=90a51516462f0, content=<a href='/topic/show?id=0c06940668a' target=_blank style='color:#2F92EE;'>#过敏症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94066, encryptionId=0c06940668a, topicName=过敏症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=def310968681, createdName=ms1948154235210413, createdTime=Thu Jul 08 10:09:27 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574835, encodeId=bcec15e48355e, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Thu Jul 08 10:09:27 CST 2021, time=2021-07-08, status=1, ipAttribution=)]
    2021-07-08 膀胱癌
  4. [GetPortalCommentsPageByObjectIdResponse(id=1761631, encodeId=e1e31e6163159, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Mar 21 23:09:27 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037495, encodeId=f51e203e4955a, content=<a href='/topic/show?id=d4189406ec0' target=_blank style='color:#2F92EE;'>#过敏症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94067, encryptionId=d4189406ec0, topicName=过敏症状)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Feb 17 13:09:27 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329524, encodeId=c8d713295244a, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Jul 08 10:09:27 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516462, encodeId=90a51516462f0, content=<a href='/topic/show?id=0c06940668a' target=_blank style='color:#2F92EE;'>#过敏症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94066, encryptionId=0c06940668a, topicName=过敏症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=def310968681, createdName=ms1948154235210413, createdTime=Thu Jul 08 10:09:27 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574835, encodeId=bcec15e48355e, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Thu Jul 08 10:09:27 CST 2021, time=2021-07-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1761631, encodeId=e1e31e6163159, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Mar 21 23:09:27 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037495, encodeId=f51e203e4955a, content=<a href='/topic/show?id=d4189406ec0' target=_blank style='color:#2F92EE;'>#过敏症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94067, encryptionId=d4189406ec0, topicName=过敏症状)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Feb 17 13:09:27 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329524, encodeId=c8d713295244a, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Jul 08 10:09:27 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516462, encodeId=90a51516462f0, content=<a href='/topic/show?id=0c06940668a' target=_blank style='color:#2F92EE;'>#过敏症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94066, encryptionId=0c06940668a, topicName=过敏症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=def310968681, createdName=ms1948154235210413, createdTime=Thu Jul 08 10:09:27 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574835, encodeId=bcec15e48355e, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Thu Jul 08 10:09:27 CST 2021, time=2021-07-08, status=1, ipAttribution=)]
    2021-07-08 qblt

相关资讯

Nat Commun:全基因组CRISPR筛选揭示乳腺癌的易感性和mTOR/Hippo协同潜在靶向治疗策略

乳腺癌作为影响全球妇女的一大疾病,其发病率和死亡率逐年上升。

BJU Int:系统靶向治疗复发性肾细胞癌中的辅助舒尼替尼治疗结果

目前还没有现有数据支持系统性靶向治疗(TT)复发肾细胞癌(RCC)患者在完成舒尼替尼辅助治疗后的可能反应。最近,有研究人员评估了在晚期阶段再次使用舒尼替尼和其他TT的有效性和耐受性。

Trends Cancer:以肠道微生物群为靶点治疗癌症患者免疫治疗引起的结肠炎

促进丁酸的益生元是预防ICI所致结肠炎的一种很有前途的新方法,甚至有可能通过增加对治疗的耐受性和促进有益于治疗的微生物种类的扩大来提高ICI治疗的疗效。

National Science Review :突破:刘红科/赵劲/郭子建提出的新策略成功实现了肿瘤内制造靶向抗癌药物

癌症是威胁人类生命健康最严重的疾病之一,抗癌药物的研发直接关乎人的生命健康。目前临床使用的抗肿瘤药物具有效率低、选择性差、毒副作用大及耐药性等缺点。

乳腺癌诊疗训练营:开班啦!CSCO BC常务委员聂建云邀您报名

👉 今晚19:30 | Class1《乳腺癌诊断的最新进展》线上开课

Blood:SARS-CoV-2特异性T细胞可快速扩增以用于临床治疗

距离2019年12月武汉报道了首例新冠病毒(SARS-CoV-2)感染已经快一年了,随着冬天的再次到来,每日新增新冠病毒感染病例持续走高。美国在总统大选的影响下,已连续4日新增病例超10万。

Baidu
map
Baidu
map
Baidu
map